Results 1 to 10 of about 21,140 (245)

Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial [PDF]

BMC Psychiatry, 2005
Background Naltrexone is an effective medication for treatment of alcohol dependence, but its efficacy is limited by lack of adherence to the oral dosage form. A long-acting depot formulation of naltrexone may increase adherence. Methods A single site, 6-
Koch Monika, Galloway Gantt P, Cello Ryan, Smith David E   +3 more
doaj   +2 more sources

A comparative study evaluating the efficacy of naltrexone versus acamprosate as anticraving agents in alcohol use disorder

Industrial Psychiatry Journal
Background: Alcohol use disorders (AUDs) are characterized by excessive alcohol consumption, negatively impacting health, social life, and economic status. Globally, AUD contributes to significant disease burden, causing millions deaths annually. Despite
Samant Singh, Lakhan Kataria, Mohd Rashid Alam   +2 more
doaj   +2 more sources

Safety of naltrexone in patients with cirrhosis

JHEP Reports
Background & Aims: Treatment of alcohol use disorder (AUD) improves survival in patients with alcohol-related cirrhosis. However, medications for alcohol use disorder (MAUD) are underutilized in this population, partially due to concerns regarding ...
Rachel Thompson, Tamar Taddei, David Kaplan, Anahita Rabiee   +3 more
doaj   +3 more sources

Naltrexone Protects Against Hypotension, Hyperthermia, and β-Endorphin Overproduction During Heatstroke in the Rat

Journal of Pharmacological Sciences, 2005
Heat stroke is characterized by hyperthermia, arterial hypotension, decreased baroreflex sensitivity, and increased serum levels of β-endorphin. Whereas naltrexone may have therapeutic potential in heat stroke, the underlying mechanism remains unclear ...
Yi-Ping Huang, Mao-Tsun Lin, Jwo-Sheng Chen, Pang-Yen Wu   +3 more
doaj   +3 more sources

Safety and Effectiveness of Naltrexone-Bupropion in Korean Adults with Obesity: Post-Marketing Surveillance Study [PDF]

Drug Design, Development and Therapy
Young Sang Lyu,1 Hongyup Ahn,2 Sangmo Hong,3 Cheol-Young Park4 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University Hospital, Gwangju, Republic of Korea; 2Department of Statistics, Dongguk University, Seoul ...
Lyu YS, Ahn H, Hong S, Park CY
doaj   +2 more sources

Demographic and Clinical Characteristics of 907 Cases with Naltrexone Intoxication; a 14-Year Cross-Sectional Study

Archives of Academic Emergency Medicine, 2022
Introduction: Opioids have been the leading cause of death from poisoning in Iran for several years. This study aimed to evaluate the clinical and para-clinical presentations of naltrexone intoxication, its toxic dose, and its epidemiological properties.
Mitra Rahimi, Alireza Kargar, Delara Hazegh Fetratjoo, Sayed Masoud Hosseini, Arezou Mahdavinejad, Shahin Shadnia   +5 more
doaj   +1 more source

Assessing Naltrexone Prescribing and Barriers to Initiation for Alcohol Use Disorder: A Multidisciplinary, Multisite Survey

Frontiers in Psychiatry, 2022
ObjectiveTo survey barriers in prescribing naltrexone for alcohol use disorder.MethodsA 12-question survey related to naltrexone prescribing patterns, perceptions, and knowledge was sent to 770 prescribers in the departments of internal medicine, family ...
Jonathan G. Leung, Prasanna P. Narayanan, Matej Markota, Nathaniel E. Miller, Kemuel L. Philbrick, M. Caroline Burton, Robert W. Kirchoff   +6 more
doaj   +1 more source

Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood. [PDF]

PLoS ONE, 2012
Naltrexone is not recommended during pregnancy. However, sustained-release naltrexone implant use in humans has resulted in cases of inadvertent foetal exposure.
Waleed O Farid, Andrew J Lawrence, Elena V Krstew, Robert J Tait, Gary K Hulse, Sarah A Dunlop   +5 more
doaj   +1 more source

Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease

Hepatology Communications, 2022
Naltrexone is an approved drug for management of alcohol use disorder (AUD), but data in patients with liver disease (LD) are limited. We aimed to evaluate the safety of naltrexone in those with LD.
Divya Ayyala, Thomas Bottyan, Christine Tien, Michael Pimienta, Jennie Yoo, Kelli Stager, Jose Luis Gonzalez, Andrew Stolz, Jennifer L. Dodge, Norah A. Terrault, Hyosun Han   +10 more
doaj   +1 more source

The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis

Frontiers in Psychiatry, 2022
BackgroundOpioid dependency is a chronic relapsing disorder for which different therapeutically interventions have been developed. Naltrexone is a non-selective opioid antagonist that can be utilized for maintenance therapy in opioid dependency.
Moein Zangiabadian, Saeid Golmohammadi, Seyed Aria Nejadghaderi, Mohammad Mahdi Zahmatkesh, Mohammad Javad Nasiri, Majid Sadeghian   +5 more
doaj   +1 more source